CL2014002773A1 - Una forma de dosificacion subcutanea de una composicion farmaceutica de un factor de coagulacion sanguinea seleccionado de factor vii, viia, viii, ix, x, xa, xi, xiii, v, factor de von willebrand y proteina c, conjugado con una molecula de polietilenglicol (peg), en donde la dosificacion del factor es de 100 y 250 ui/kg o 25 y 50 ui/kg, y en donde la molecula de peg se conjuga directa o indirectamente. - Google Patents
Una forma de dosificacion subcutanea de una composicion farmaceutica de un factor de coagulacion sanguinea seleccionado de factor vii, viia, viii, ix, x, xa, xi, xiii, v, factor de von willebrand y proteina c, conjugado con una molecula de polietilenglicol (peg), en donde la dosificacion del factor es de 100 y 250 ui/kg o 25 y 50 ui/kg, y en donde la molecula de peg se conjuga directa o indirectamente.Info
- Publication number
- CL2014002773A1 CL2014002773A1 CL2014002773A CL2014002773A CL2014002773A1 CL 2014002773 A1 CL2014002773 A1 CL 2014002773A1 CL 2014002773 A CL2014002773 A CL 2014002773A CL 2014002773 A CL2014002773 A CL 2014002773A CL 2014002773 A1 CL2014002773 A1 CL 2014002773A1
- Authority
- CL
- Chile
- Prior art keywords
- factor
- peg
- conjugated
- molecule
- viia
- Prior art date
Links
- 108010039209 Blood Coagulation Factors Proteins 0.000 title 1
- 102000015081 Blood Coagulation Factors Human genes 0.000 title 1
- 239000002202 Polyethylene glycol Substances 0.000 title 1
- 239000003114 blood coagulation factor Substances 0.000 title 1
- 229940019700 blood coagulation factors Drugs 0.000 title 1
- 229940012413 factor vii Drugs 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 229920001223 polyethylene glycol Polymers 0.000 title 1
- 229960000856 protein c Drugs 0.000 title 1
- 239000006203 subcutaneous dosage form Substances 0.000 title 1
- 108010047303 von Willebrand Factor Proteins 0.000 title 1
- 102100036537 von Willebrand factor Human genes 0.000 title 1
- 229960001134 von willebrand factor Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
- A61K38/37—Factors VIII
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Zoology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dermatology (AREA)
- Diabetes (AREA)
- Dispersion Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Endocrinology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1206628.8A GB201206628D0 (en) | 2012-04-16 | 2012-04-16 | Subcutaneous administration of PEGylated blood clotting factors |
| GBGB1213712.1A GB201213712D0 (en) | 2012-08-01 | 2012-08-01 | Modified therapeutic agents |
| GBGB1214985.2A GB201214985D0 (en) | 2012-08-22 | 2012-08-22 | Modified therapeutic agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2014002773A1 true CL2014002773A1 (es) | 2015-01-16 |
Family
ID=48190923
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2014002773A CL2014002773A1 (es) | 2012-04-16 | 2014-10-15 | Una forma de dosificacion subcutanea de una composicion farmaceutica de un factor de coagulacion sanguinea seleccionado de factor vii, viia, viii, ix, x, xa, xi, xiii, v, factor de von willebrand y proteina c, conjugado con una molecula de polietilenglicol (peg), en donde la dosificacion del factor es de 100 y 250 ui/kg o 25 y 50 ui/kg, y en donde la molecula de peg se conjuga directa o indirectamente. |
Country Status (29)
| Country | Link |
|---|---|
| US (2) | US20150086524A1 (enExample) |
| EP (1) | EP2838566A2 (enExample) |
| JP (3) | JP2015512927A (enExample) |
| KR (1) | KR102137290B1 (enExample) |
| CN (1) | CN104411335A (enExample) |
| AP (1) | AP2014008049A0 (enExample) |
| AU (3) | AU2013248296A1 (enExample) |
| BR (1) | BR112014025737A2 (enExample) |
| CA (1) | CA2869993C (enExample) |
| CL (1) | CL2014002773A1 (enExample) |
| CO (1) | CO7151496A2 (enExample) |
| CR (1) | CR20140475A (enExample) |
| EA (1) | EA033469B1 (enExample) |
| EC (1) | ECSP14023048A (enExample) |
| GB (3) | GB201910190D0 (enExample) |
| GE (1) | GEP201706716B (enExample) |
| HK (1) | HK1200695A1 (enExample) |
| IL (1) | IL235129B (enExample) |
| IN (1) | IN2014DN08598A (enExample) |
| MD (1) | MD20140123A2 (enExample) |
| MX (2) | MX2014012512A (enExample) |
| MY (1) | MY190257A (enExample) |
| NI (1) | NI201400122A (enExample) |
| NZ (1) | NZ701205A (enExample) |
| PE (1) | PE20150226A1 (enExample) |
| PH (1) | PH12014502314B1 (enExample) |
| SG (1) | SG11201406492YA (enExample) |
| WO (1) | WO2013156488A2 (enExample) |
| ZA (1) | ZA201407370B (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104073482A (zh) * | 2013-12-30 | 2014-10-01 | 江苏众红生物工程创药研究院有限公司 | 聚乙二醇化的组织激肽释放酶及其制备方法和应用 |
| GB201417589D0 (en) | 2014-10-06 | 2014-11-19 | Cantab Biopharmaceuticals Patents Ltd | Pharmaceutical Formulations |
| FR3034669B1 (fr) * | 2015-04-07 | 2020-02-14 | Laboratoire Francais Du Fractionnement Et Des Biotechnologies | Nouvelle utilisation du facteur von willebrand |
| WO2016198641A1 (en) * | 2015-06-12 | 2016-12-15 | Laboratoire Francais Du Fractionnement Et Des Biotechnologies | Injectable composition of factor vii and fillers |
| GB201518172D0 (en) | 2015-10-14 | 2015-11-25 | Cantab Biopharmaceuticals Patents Ltd | Colloidal particles for use in medicine |
| GB201518171D0 (en) | 2015-10-14 | 2015-11-25 | Cantab Biopharmaceuticals Patents Ltd | Colloidal particles for topical administration with therapeutic agent |
| GB201518170D0 (en) | 2015-10-14 | 2015-11-25 | Cantab Biopharmaceuticals Patents Ltd | Colloidal particles for subcutaneous administration with intravenous administration of therapeutic agent |
| CN109998994B (zh) * | 2018-02-13 | 2021-12-07 | 四川大学 | 包含药物的柔性脂质体及其制备方法 |
| US20230190881A1 (en) | 2020-02-17 | 2023-06-22 | Biotest Ag | Subcutaneous administration of factor viii |
| JP2023523927A (ja) * | 2020-04-23 | 2023-06-08 | イーライ リリー アンド カンパニー | 抗体の皮下吸収及びバイオアベイラビリティ |
Family Cites Families (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1479268A (en) | 1973-07-05 | 1977-07-13 | Beecham Group Ltd | Pharmaceutical compositions |
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| CH596313A5 (enExample) | 1975-05-30 | 1978-03-15 | Battelle Memorial Institute | |
| US4414147A (en) | 1981-04-17 | 1983-11-08 | Massachusetts Institute Of Technology | Methods of decreasing the hydrophobicity of fibroblast and other interferons |
| US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
| WO1987000056A1 (en) | 1985-06-26 | 1987-01-15 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polymer conjugation |
| WO1990015628A1 (en) * | 1989-06-14 | 1990-12-27 | Cetus Corporation | Polymer/antibiotic conjugate |
| AU5098193A (en) | 1992-09-01 | 1994-03-29 | Berlex Laboratories, Inc. | Glycolation of glycosylated macromolecules |
| WO1994007910A1 (en) | 1992-09-28 | 1994-04-14 | Research Corporation Technologies, Inc. | New reagents for peptide couplings |
| US5621039A (en) * | 1993-06-08 | 1997-04-15 | Hallahan; Terrence W. | Factor IX- polymeric conjugates |
| IL113010A (en) * | 1994-03-31 | 1999-10-28 | Pharmacia & Upjohn Ab | Pharmaceutical formulation comprising factor viii with an activity of at least 500iu/ml and an enhancer for improved subcutaneous intramuscular or intradermal administration |
| JPH0892294A (ja) * | 1994-09-29 | 1996-04-09 | Teijin Ltd | ヒト活性化プロテインｃ誘導体 |
| US5693609A (en) | 1994-11-17 | 1997-12-02 | Eli Lilly And Company | Acylated insulin analogs |
| CA2177644A1 (en) * | 1995-05-31 | 1996-12-01 | Peter D. Senter | Polymeric prodrugs for beta-lactamase and uses thereof |
| SE9503380D0 (sv) * | 1995-09-29 | 1995-09-29 | Pharmacia Ab | Protein derivatives |
| ATE200030T1 (de) | 1997-01-29 | 2001-04-15 | Polymasc Pharmaceuticals Plc | Pegylationsverfahren |
| AU2605099A (en) * | 1998-02-25 | 1999-09-15 | Micrologix Biotech, Inc. | Indolicidin and cationic peptides conjugated with polymers |
| WO2001058935A2 (en) * | 2000-02-11 | 2001-08-16 | Maxygen Aps | FACTOR VII OR VIIa-LIKE MOLECULES |
| EP1280548B1 (en) | 2000-05-03 | 2013-12-11 | Novo Nordisk Health Care AG | Subcutaneous administration of coagulation factor VII |
| US20030211094A1 (en) * | 2001-06-26 | 2003-11-13 | Nelsestuen Gary L. | High molecular weight derivatives of vitamin k-dependent polypeptides |
| MXPA04012496A (es) | 2002-06-21 | 2005-09-12 | Novo Nordisk Healthcare Ag | Glicoformos del factor vii pegilados. |
| UA86744C2 (en) * | 2002-06-21 | 2009-05-25 | Ново Нордиск Хэлс Кеа Аг | Pegylated factor vii glycoforms |
| AU2004215912B2 (en) * | 2003-02-26 | 2009-03-26 | Nektar Therapeutics | Polymer-factor VIII moiety conjugates |
| EP1620118B1 (en) * | 2003-04-08 | 2014-06-18 | Yeda Research And Development Co., Ltd. | Reversible pegylated drugs |
| US20130137157A1 (en) * | 2003-04-09 | 2013-05-30 | Novo Nordisk A/S | Glycopegylated factor vii and factor viia |
| GB0316294D0 (en) | 2003-07-11 | 2003-08-13 | Polytherics Ltd | Conjugated biological molecules and their preparation |
| US20060198819A1 (en) | 2003-08-08 | 2006-09-07 | Novo Nordisk Healthcare A/G | Use of galactose oxidase for selective chemical conjugation of protractor molecules to proteins of therapeutic interest |
| JPWO2005084679A1 (ja) | 2004-03-04 | 2007-11-29 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | ベンズアミジン誘導体含有組成物及びベンズアミジン誘導体の安定化方法 |
| KR101146160B1 (ko) * | 2004-06-30 | 2012-07-16 | 넥타르 테라퓨틱스 | 중합체인자 ｉｘ 부분의 접합체 |
| US20090176967A1 (en) | 2004-08-02 | 2009-07-09 | Novo Nordisk Healthcare A/G | Conjugation of FVII |
| EP2975135A1 (en) | 2005-05-25 | 2016-01-20 | Novo Nordisk A/S | Glycopegylated factor IX |
| ES2553160T3 (es) | 2005-06-17 | 2015-12-04 | Novo Nordisk Health Care Ag | Reducción y derivatización selectivas de proteínas Factor VII transformadas por ingeniería que comprenden al menos una cisteína no nativa |
| JP2009515508A (ja) * | 2005-08-19 | 2009-04-16 | ネオス テクノロジーズ インコーポレイテッド | グリコｐｅｇ化因子ｖｉｉおよび因子ｖｉｉａ |
| CA2647314A1 (en) * | 2006-03-31 | 2007-11-08 | Baxter International Inc. | Pegylated factor viii |
| US20100056428A1 (en) | 2006-09-01 | 2010-03-04 | Novo Nordisk Health Care Ag | Modified proteins |
| CA2670618C (en) | 2006-12-15 | 2016-10-04 | Baxter International Inc. | Factor viia- (poly) sialic acid conjugate having prolonged in vivo half-life |
| EP2114458B1 (en) * | 2006-12-27 | 2014-02-26 | Nektar Therapeutics | Von willebrand factor- and factor viii-polymer conjugates having a releasable linkage |
| WO2008081024A1 (en) | 2007-01-03 | 2008-07-10 | Novo Nordisk Health Care Ag | Subcutaneous administration of coagulation factor viia-related popypeptdes |
| WO2008119815A1 (en) * | 2007-04-02 | 2008-10-09 | Novo Nordisk A/S | Subcutaneous administration of coagulation factor ix |
| KR20100016462A (ko) | 2007-04-13 | 2010-02-12 | 카탈리스트 바이오사이언시즈, 인코포레이티드 | 변형 제ｖｉｉ 인자 폴리펩타이드 및 이의 용도 |
| EP2014299A1 (en) | 2007-07-11 | 2009-01-14 | Novo Nordisk A/S | Subcutaneous administration of coagulation factor VII |
| ES2597849T3 (es) | 2007-10-09 | 2017-01-23 | Polytherics Limited | Proteínas y péptidos conjugados novedosos |
| EP2209801B1 (en) | 2007-10-16 | 2013-01-16 | Pharmacyclics, Inc. | Manufacture, compositions and uses of coagulationfactor viia modulator |
| CN101965200B (zh) | 2008-02-27 | 2013-06-19 | 诺沃-诺迪斯克有限公司 | 缀合的因子ⅷ分子 |
| TWI538916B (zh) | 2008-04-11 | 2016-06-21 | 介控生化科技公司 | 經修飾的因子vii多肽和其用途 |
| JP2011517950A (ja) * | 2008-04-16 | 2011-06-23 | バイエル・ヘルスケア・エルエルシー | 第ｉｘ因子の部位特異的修飾 |
| AU2009239641B2 (en) * | 2008-04-24 | 2013-11-07 | Cantab Biopharmaceuticals Patents Limited | Factor IX conjugates with extended half-lives |
| WO2009141433A1 (en) * | 2008-05-23 | 2009-11-26 | Novo Nordisk Health Care Ag | Low viscosity compositions comprising a pegylated gla-domain containing protein |
| AU2009275358C1 (en) | 2008-07-21 | 2015-09-24 | Polytherics Limited | Novel reagents and method for conjugating biological molecules |
| AU2009303368B2 (en) * | 2008-10-15 | 2012-04-05 | Takeda Pharmaceutical Company Limited | Pegylation of recombinant blood coagulation factors in the presence of bound antibodies |
| KR101929641B1 (ko) * | 2008-10-17 | 2018-12-14 | 박스알타 인코퍼레이티드 | 낮은 수준의 수용성 중합체를 포함하는 개질된 혈액 인자 |
| CA2748662A1 (en) * | 2009-01-19 | 2010-07-22 | Bayer Healthcare Llc | Protein conjugate having an endopeptidase-cleavable bioprotective moiety |
| NZ598056A (en) * | 2009-07-27 | 2014-01-31 | Baxter Int | Blood coagulation protein conjugates |
| US20130040888A1 (en) * | 2010-02-16 | 2013-02-14 | Novo Nordisk A/S | Factor VIII Molecules With Reduced VWF Binding |
| GB201007357D0 (en) * | 2010-04-30 | 2010-06-16 | Leverton Licence Holdings Ltd | Conjugated factor VIII |
| GB201007356D0 (en) * | 2010-04-30 | 2010-06-16 | Leverton Licence Holdings Ltd | Conjugated factor VIIa |
| BR112013001611B1 (pt) * | 2010-07-30 | 2022-05-10 | Takeda Pharmaceutical Company Limited | Método para conjugar um polímero solúvel em água a uma fração de carboidrato oxidado de uma proteína terapêutica, proteína terapêutica modificada, método para formar uma ligação oxima entre uma fração de carboidrato oxidado em uma proteína terapêutica e um polímero solúvel em água ativado contendo um grupo amino-óxi ativo emétodo para formar uma ligação hidrazona entre uma fração de carboidrato oxidado em uma proteína terapêutica e um polímero solúvel em água ativado contendo um grupo hidrazida ativo |
| WO2012088123A1 (en) * | 2010-12-22 | 2012-06-28 | Nektar Therapeutics | Polymer-factor vii moiety conjugates |
-
2013
- 2013-04-16 MD MD20140123A patent/MD20140123A2/ro unknown
- 2013-04-16 GB GBGB1910190.6A patent/GB201910190D0/en not_active Ceased
- 2013-04-16 PE PE2014001639A patent/PE20150226A1/es active IP Right Grant
- 2013-04-16 MX MX2014012512A patent/MX2014012512A/es unknown
- 2013-04-16 CN CN201380027958.3A patent/CN104411335A/zh active Pending
- 2013-04-16 GB GBGB1910184.9A patent/GB201910184D0/en not_active Ceased
- 2013-04-16 EA EA201491702A patent/EA033469B1/ru unknown
- 2013-04-16 HK HK15100881.5A patent/HK1200695A1/xx unknown
- 2013-04-16 AU AU2013248296A patent/AU2013248296A1/en not_active Abandoned
- 2013-04-16 EP EP13719043.5A patent/EP2838566A2/en active Pending
- 2013-04-16 JP JP2015504987A patent/JP2015512927A/ja active Pending
- 2013-04-16 IN IN8598DEN2014 patent/IN2014DN08598A/en unknown
- 2013-04-16 CA CA2869993A patent/CA2869993C/en active Active
- 2013-04-16 GE GEAP201313632A patent/GEP201706716B/en unknown
- 2013-04-16 GB GB1418864.3A patent/GB2516388A/en not_active Withdrawn
- 2013-04-16 SG SG11201406492YA patent/SG11201406492YA/en unknown
- 2013-04-16 WO PCT/EP2013/057928 patent/WO2013156488A2/en not_active Ceased
- 2013-04-16 NZ NZ701205A patent/NZ701205A/en not_active IP Right Cessation
- 2013-04-16 BR BR112014025737A patent/BR112014025737A2/pt not_active Application Discontinuation
- 2013-04-16 MY MYPI2014002900A patent/MY190257A/en unknown
- 2013-04-16 US US14/394,437 patent/US20150086524A1/en not_active Abandoned
- 2013-04-16 KR KR1020147031042A patent/KR102137290B1/ko active Active
- 2013-04-16 IL IL235129A patent/IL235129B/en unknown
- 2013-04-16 AP AP2014008049A patent/AP2014008049A0/xx unknown
-
2014
- 2014-10-10 ZA ZA2014/07370A patent/ZA201407370B/en unknown
- 2014-10-14 CR CR20140475A patent/CR20140475A/es unknown
- 2014-10-15 CL CL2014002773A patent/CL2014002773A1/es unknown
- 2014-10-15 NI NI201400122A patent/NI201400122A/es unknown
- 2014-10-15 PH PH12014502314A patent/PH12014502314B1/en unknown
- 2014-10-16 MX MX2020014208A patent/MX2020014208A/es unknown
- 2014-10-16 EC ECIEPI201423048A patent/ECSP14023048A/es unknown
- 2014-11-14 CO CO14252826A patent/CO7151496A2/es unknown
-
2017
- 2017-08-30 US US15/691,090 patent/US11351112B2/en active Active
- 2017-09-06 JP JP2017171545A patent/JP6550107B2/ja active Active
-
2018
- 2018-01-05 AU AU2018200111A patent/AU2018200111B2/en not_active Ceased
-
2019
- 2019-04-05 JP JP2019073048A patent/JP2019131593A/ja active Pending
-
2020
- 2020-02-06 AU AU2020200842A patent/AU2020200842A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2014002773A1 (es) | Una forma de dosificacion subcutanea de una composicion farmaceutica de un factor de coagulacion sanguinea seleccionado de factor vii, viia, viii, ix, x, xa, xi, xiii, v, factor de von willebrand y proteina c, conjugado con una molecula de polietilenglicol (peg), en donde la dosificacion del factor es de 100 y 250 ui/kg o 25 y 50 ui/kg, y en donde la molecula de peg se conjuga directa o indirectamente. | |
| CY1124436T1 (el) | Δικυκλικες ετεροκυκλικες ενωσεις και χρησεις αυτων στη θεραπεια | |
| CY1123675T1 (el) | Πολυαιθυλενογλυκολιωμενου φαρμακου-συνδετες για βελτιωμενες φαρμακοκινητικες προϊοντος συζευξης προσδετη-φαρμακου | |
| EP3835296A4 (en) | KETOAMIDE COMPOUND AND METHOD FOR THE PREPARATION, PHARMACEUTICAL COMPOSITION AND USE THEREOF | |
| MX2020000083A (es) | Factor de von willebrand recombinante ( rvwf ) y factor viii recombinante ( rfviii ) para usarse en un metodo para tratar la enfermedad de von willebrand. | |
| PE20140616A1 (es) | Composicion que comprende aflibercept, acido folinico, 5-fluorouracilo (5-fu) e irinotecan (folfiri) | |
| CL2012003340A1 (es) | Composicion farmaceutica de administracion oral de bendamustina y su uso en el tratamiento oral de una condicion medica seleccionada de leucemia linfocitica cronica, cancer de mama, entre otras. | |
| EP2983659A4 (en) | ACTIVE DERIVATIVE POLYMER AND USES THEREOF | |
| EA201890417A1 (ru) | Генетически кодируемые, внутренне неупорядоченные полимеры-"невидимки" для доставки и способы их применения | |
| CL2014001858A1 (es) | Compuestos derivados de pirrolidina-2-carboxamidas sustituidas, antagonistas de mdm2; composicion farmacetica; y su uso en el tratamiento o profilaxis del cancer. | |
| CY1120098T1 (el) | Συνθεσεις που περιεχουν βορτιοξετινη και δονεπεζιλη | |
| MX381365B (es) | Composiciones de resina reciclada y dispositivos medicos desechables preparados a partir de las anteriores. | |
| EP3318282A4 (en) | AGGREGATE COMPOSITION CARRIER AND COMPOSITION THEREOF | |
| MY160510A (en) | Polyethylene gycol conjugated blood coagulation factor viia | |
| CY1114190T1 (el) | Νεα μορφη χορηγησης της ρασεκαδοτριλης | |
| CL2014003148A1 (es) | Composición farmacéutica acuosa que contiene un agente terapéutico biológico y guanidina o un derivado de la guanidina y una inyección que incluye la composición. | |
| EP3556352A4 (en) | COMPOSITION OF AMPHIPHILIC SEQUENCED COPOLYMER WITH IMPROVED MICELLAR STABILITY AND PHARMACEUTICAL COMPOSITION COMPRISING IT | |
| CL2012003322A1 (es) | Compuestos derivados de benzamida sustituidas; composicion farmacéutica; y uso en el tratamiento del cancer. | |
| MX2017014503A (es) | Polipeptidos de factor de von willebrand truncado para tratar hemofilia. | |
| MX389026B (es) | Una composicion farmaceutica y el uso de la misma. | |
| CY1121566T1 (el) | Νευροπροστατευτικο και ενδειξη αυτου | |
| IL269962A (en) | Article of manufacture comprising local anesthetic, buffer, and glycosaminoglycan in syringe with improved stability | |
| EA201691860A1 (ru) | Пептидный медикамент в виде сухого порошка | |
| MX375186B (es) | Composiciones de anfetamina transdérmica estable y métodos de fabricación. | |
| PL3648788T3 (pl) | Leczenie krwawienia z przewodu pokarmowego u pacjentów z ciężką chorobą von willebranda poprzez podanie rekombinowanego vwf |